FULC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fulcrum Therapeutics Inc (FULC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive catalysts, strong analyst support, and promising data from its PIONEER study, which could lead to significant growth in the future. Despite weak financials, the long-term potential outweighs the short-term challenges.
The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 64.607, indicating no overbought or oversold conditions. The stock is trading near its resistance level (R1: 10.96) with converging moving averages, which may signal a potential breakout. Support levels are S1: 9.608 and S2: 9.19.
Strong analyst sentiment with multiple price target increases, including a high target of $
Positive data from the Phase 1b PIONEER study for pociredir in sickle cell disease, showing strong efficacy and tolerability.
Potential to become a leading oral therapy in the SCD market.
Removal of a competitor (Agios) in the SCD space, enhancing Fulcrum's market positioning.
Weak financial performance in Q3 2025, with negative net income (-$19.6M), declining EPS (-11.43% YoY), and no revenue growth.
High implied volatility (126.
and low IV rank (34.
suggest uncertainty and limited historical price movement relative to current expectations.
In Q3 2025, Fulcrum reported no revenue growth (0% YoY), a net income loss of -$19.6M (-9.68% YoY), and a drop in EPS to -0.31 (-11.43% YoY). Gross margin also dropped to 0, reflecting no profitability. However, these financials are typical for a biotech company in the clinical trial phase.
Analysts are highly optimistic about Fulcrum, with several firms raising price targets significantly (e.g., Stifel to $25, Cantor Fitzgerald to $24, Piper Sandler to $23). The consensus is positive due to promising PIONEER data and the potential for long-term growth in the SCD market.
